A bipartisan bill introduced by the leaders of the Senate Diabetes Caucus aims to curb the pricing of life-saving insulin by capping monthly co-pays for diabetics who use both commercial insurance plans, as well as the government-backed Medicare.
https://www.pharmalive.com/wp-content/uploads/2022/05/Editas-Neurocrine-Snag-Orphan-Drug-Designations-as-Congressional-Debate-Continues-BioSpace-5-13-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-06-22 11:23:202022-06-22 11:23:20Bipartisan Senate bill aims to lower insulin costs